IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(11):2497-2505

Original Article
High expression of biglycan is associated with poor prognosis in patients with
esophageal squamous cell carcinoma

Ying-Hui Zhu, Fu Yang, Shui-Shen Zhang, Ting-Ting Zeng, Xuan Xie, Xin-Yuan Guan

State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Clinical
Oncology, Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Received August 30, 2013; Accepted October 12, 2013; Epub October 15, 2013; Published November 1, 2013

Abstract: Biglycan (BGN), an extracellular matrix component, has been reported to play a crucial role in the tumor progression of various
cancers. However, the relation between the expression of BGN and clinical prognosis has not been studied yet. We therefore carry out the
present study to elucidate the role of BGN in predicting outcomes of patients with esophageal squamous cell carcinoma (ESCC). In this study,
the expression of BGN in 170 cases of ESCC tissues and matched 46 adjacent non-tumorous tissues was measured by quantitative real-time
PCR and immunohistochemistry. Upregulation of BGN occurred in approximately 60% of primary ESCCs compared with their non-tumor
counterparts. In addition, high expression of BGN was significantly associated with clinical stage (P = 0.009), tumor invasion (P = 0.006) and
lymph node metastasis (P = 0.046). The 5-year disease-specific survival (DSS) in high expression of BGN group is poorer than that in low level
expression group (36.8% VS 57.4%, P = 0.006). Stratified analysis according to the pathological stage revealed its discernibility on DSS was
only pronounced in patients with advanced clinical stage (P = 0.010). Cox multivariate analysis revealed that pathologic N category (P < 0.001;
hazard ratio, 2.482, 95% CI, 1.576-3.909) and BGN expression (P = 0.019; hazard ratio, 1.713, 95% CI, 1.092-2.688) were two independent
prognostic factors. The findings of the present study provide evidence that BGN represents a potential novel prognostic biomarker for resected
ESCC patients in advanced clinical stage. (IJCEP1308072).

Keywords: BGN, ESCC, prognosis

Address Correspondence to: Dr. Xin-Yuan Guan, Department of Clinical Oncology, Faculty of Medicine, The University of Hong Kong, L10-56,
Laboratory Block, 21 Sassoon Road, Hong Kong, China. Tel: 852-28199782; E-mail: xyguan@hkucc.hku.hk; Dr. Ying-Hui Zhu, State Key
Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Center, Room 605, 651 Dongfeng East Road, Guangzhou, 510060,
China. Tel: 86-20-87343165; E-mail: zhuyh@sysucc.org.cn